Osaka, Japan

Aki Kiyomiya

This inventor holds 1 USPTO granted patent. Top assignee: Rohto Pharmaceutical Co., Ltd.. Active years: 2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aki Kiyomiya. Retrieved from https://idiyas.com/inventor/aki-kiyomiya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aki Kiyomiya: Innovator in Ophthalmic Composition

Introduction

Aki Kiyomiya is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of ophthalmic compositions, showcasing his innovative spirit and dedication to improving user experience in eye care products.

Latest Patents

Kiyomiya holds a patent for an ophthalmic composition that includes polyvinyl pyrrolidone K90 and at least one component selected from oil, grease, or polyethylene glycol. This inventive formulation alleviates a sticky sensation, ensuring an excellent use experience for consumers.

Career Highlights

Kiyomiya is associated with Rohto Pharmaceutical Co., Ltd., a company known for its commitment to developing high-quality healthcare products. His work has contributed to the advancement of ophthalmic solutions, enhancing the comfort and effectiveness of eye care.

Collaborations

Some of his coworkers include Takahiro Kurose and Atsuko Nakata, who collaborate with him in various projects at Rohto Pharmaceutical Co., Ltd.

Conclusion

Aki Kiyomiya's innovative contributions to ophthalmic compositions reflect his commitment to enhancing user experience in eye care. His patent demonstrates the potential for improved formulations in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…